The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability

Cancer Research

Volumn 61, Issue 18, 2001, Pages 6811-6815

  Beauregard, Daniel A ^a   Hill, Sally A ^b   Chaplin, Dai J ^b   Brindle, Kevin M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN A4; CONTRAST MEDIUM; GADOLINIUM PENTETATE; PHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; GENETIC HETEROGENEITY; MOUSE; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; TUMOR VASCULARIZATION; VASCULAR RESISTANCE;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAPILLARY PERMEABILITY; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED CBA; MICE, SCID; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORUS; STILBENES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035884395     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4
2. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
3. Combretastatin A4 phosphate (CA4P) selectively targets vasculature in animal and human tumors
4. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific agent combretastatin A-4
5. 4 prodrug-induced disruption of tumour perfusion and energetic status
6. Determinants of anti-vascular action by combretastatin A-4 phosphate: Role of nitric oxide
7. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues
8. Angiogenesis in cancer and other diseases
9. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
10. Combretastatin A4 phosphate (CA4P) targets vasculature in animal and human tumours
11. Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumours
12. Assessing tumor angiogenesis using macromolecular MR imaging contrast media
13. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor
14. In vivo assessment of vascular endothelial growth factor-induced angiogenesis
15. In vivo prediction of vascular susceptibility to vascular endothelial growth factor withdrawal: Magnetic resonance imaging of C6 rat glioma in nude mice
16. Insights into tumor vascularization using magnetic resonance imaging and spectroscopy
17. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: Status report
18. A new mouse tumor model system (RIF-1) for comparison of end-point studies
19. Vascular occlusion and tumour cell death
20. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs
21. Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: Preparation and characterization
22. Quantitative MRI of Gd-DTPA uptake in tumours: Response to photodynamic therapy
23. Albumin labeled with Gd-DTPA as an intravascular, blood pool-enhancing agent for MR imaging: Biodistribution and imaging studies
24. Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: Comparison of macromolecular and small-molecular contrast media
25. Measurement of vascular volume fraction and blood-tissue permeability constants with a pharmacokinetic model: Studies in rat muscle tumors with dynamic Gd-DTPA enhanced MRI
26. Modification of metabolism of transplantable and spontaneous murine tumors by the nitric oxide synthase inhibitor, nitro-L-arginine
27. Determinants of tumor blood flow: A review
28. A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability
29. Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography
30. MR studies of tumours: Relationship between blood flow, metabolism, and physiology